Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Orphanet J Rare Dis. 2019 May 2;14(1):93. doi: 10.1186/s13023-019-1065-x.
Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) comprises a group of rare, lysosomal storage diseases caused by the deficiency of one of four enzymes involved in the degradation of heparan sulfate. The clinical hallmark of the disease is severe neurological deterioration leading to dementia and death in the second decade of life. Adult MPS patients are generally of short stature. To date there is no clear description of the physical development of MPS III patients. The aim of this study was to document growth reference data for MPS III patients. We collected growth data of 182 German MPS III patients and were able to develop growth charts for this cohort. Growth curves for height, weight, head circumference, and body mass index were calculated and compared to German reference charts.
Birth height, weight and head circumference were within the physiological ranges. Both genders were significantly taller than healthy children at 2 years of age, while only male patients were taller at the age of four. Growth velocity decelerated after the ages of 4.5 and 5 years for female and male patients, respectively. Both genders were significantly shorter than the reference group at the age of 17.5 years. Head circumference was larger compared to healthy matched controls within the first 2 years of life and remained enlarged until physical maturity.
MPS III is a not yet treatable severe neuro-degenerative disease, developing new therapeutic strategies might change the course of the disease significantly. The present charts contribute to the understanding of the natural history of MPS III. Specific growth charts represent an important tool for families and physicians as the expected height at physical maturity can be estimated and therapeutic effects can be monitored.
黏多糖贮积症(MPS)III 型(Sanfilippo 综合征)是一组罕见的溶酶体贮积病,由参与硫酸乙酰肝素降解的四种酶中的一种缺乏引起。该疾病的临床特征是严重的神经恶化,导致患者在生命的第二个十年内痴呆和死亡。成年 MPS 患者通常身材矮小。迄今为止,尚无关于 MPS III 患者身体发育的明确描述。本研究旨在为 MPS III 患者建立生长参考数据。我们收集了 182 名德国 MPS III 患者的生长数据,并能够为该队列制定生长图表。计算并比较了身高、体重、头围和体重指数的生长曲线与德国参考图表。
出生时的身高、体重和头围均在生理范围内。两性在 2 岁时均明显高于健康儿童,而只有男性在 4 岁时更高。生长速度在 4.5 岁和 5 岁后分别减慢。两性在 17.5 岁时均明显低于参考组。头围在生命的前 2 年内大于健康匹配对照,并且在身体成熟之前一直保持增大。
MPS III 是一种尚未可治疗的严重神经退行性疾病,开发新的治疗策略可能会显著改变疾病的进程。目前的图表有助于了解 MPS III 的自然病史。特定的生长图表是家庭和医生的重要工具,因为可以估计身体成熟时的预期身高,并可以监测治疗效果。